1. Home
  2. NTWK vs RNTX Comparison

NTWK vs RNTX Comparison

Compare NTWK & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetSol Technologies Inc.

NTWK

NetSol Technologies Inc.

HOLD

Current Price

$3.46

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$1.63

Market Cap

42.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTWK
RNTX
Founded
1997
2001
Country
United States
United States
Employees
N/A
10
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
42.9M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
NTWK
RNTX
Price
$3.46
$1.63
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
26.3K
114.9K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
316.67
N/A
EPS
N/A
N/A
Revenue
$73,088,687.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.40
N/A
52 Week Low
$2.26
$1.02
52 Week High
$5.75
$2.22

Technical Indicators

Market Signals
Indicator
NTWK
RNTX
Relative Strength Index (RSI) 50.01 68.31
Support Level $2.89 $1.08
Resistance Level $3.70 $2.18
Average True Range (ATR) 0.16 0.18
MACD -0.01 0.03
Stochastic Oscillator 56.29 89.83

Price Performance

Historical Comparison
NTWK
RNTX

About NTWK NetSol Technologies Inc.

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: